Optical coherence tomography to measure the progression of myelopathy in adrenoleukodystrophy.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
03
03
2021
received:
29
12
2020
accepted:
05
03
2021
pubmed:
31
3
2021
medline:
13
1
2022
entrez:
30
3
2021
Statut:
ppublish
Résumé
To prospectively determine the value of optical coherence tomography (OCT) as a surrogate outcome measure for the progression of myelopathy in males with adrenoleukodystrophy. Retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) thickness were measured at baseline, 1- and 2-year follow-up in patients and age-matched controls. We assessed the severity of myelopathy with clinical parameters: Expanded Disability Status Scale (EDSS), Severity Scoring system for Progressive Myelopathy (SSPROM), and timed up-and-go. Linear mixed model analysis was used to compare changes in retinal layer thickness of patients to controls. In addition, we correlated changes in retinal layer thickness with changes in clinical parameters. Longitudinal data were available for 28 patients and 29 controls. Peripapillary RNFL (pRNFL) thickness decreased significantly in patients compared to controls (-1.75µm, p = 0.001), whereas change in macular GCL and RNFL was not different between groups. Analysis of the symptomatic subgroup showed that, apart from a similar decrease in pRNFL thickness, GCL thickness decreased significantly (-0.55 µm, p = 0.014). There were moderately strong correlations between changes in retinal layer thickness and changes in clinical parameters of severity of myelopathy. This prospective study demonstrates the potential of OCT-measured retinal neurodegeneration as a surrogate outcome measure for the progression of myelopathy in adrenoleukodystrophy. As differences were small, our findings need to be confirmed with longer follow-up and/or in a larger patient sample.
Identifiants
pubmed: 33784026
doi: 10.1002/acn3.51349
pmc: PMC8108423
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1064-1072Informations de copyright
© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
PLoS One. 2012;7(4):e34823
pubmed: 22536333
Pediatr Res. 1984 Mar;18(3):286-90
pubmed: 6728562
Neurol Clin Pract. 2015 Oct;5(5):460-469
pubmed: 29443181
J Neuropathol Exp Neurol. 2000 Feb;59(2):89-102
pubmed: 10749098
J Neurol. 2020 Mar;267(3):679-687
pubmed: 31720823
BMC Neurol. 2014 Mar 25;14:58
pubmed: 24666846
Dev Neurosci. 1991;13(4-5):254-61
pubmed: 1817030
Orphanet J Rare Dis. 2019 Feb 7;14(1):30
pubmed: 30732635
Arch Phys Med Rehabil. 2005 Feb;86(2):190-6
pubmed: 15706542
Mult Scler. 2017 Apr;23(4):597-603
pubmed: 27364325
Neurology. 1990 Jun;40(6):971-5
pubmed: 2189084
Arch Neurol. 1988 Jul;45(7):746-8
pubmed: 3390030
Nature. 1993 Feb 25;361(6414):726-30
pubmed: 8441467
J Glaucoma. 2013 Jun-Jul;22 Suppl 5:S2-7
pubmed: 23733119
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
Brain. 2019 Feb 1;142(2):334-343
pubmed: 30535170
Neurol Sci. 2021 Jan;42(1):235-241
pubmed: 32632637
JAMA Neurol. 2018 Oct 1;75(10):1256-1263
pubmed: 29946702
Nat Rev Endocrinol. 2016 Oct;12(10):606-15
pubmed: 27312864
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Arch Ophthalmol. 1996 Sep;114(9):1079-84
pubmed: 8790092
Braz J Med Biol Res. 2012 Jul;45(7):565-72
pubmed: 22570090
Lancet Neurol. 2017 Oct;16(10):797-812
pubmed: 28920886
Brain. 2014 Mar;137(Pt 3):693-706
pubmed: 24480483
Orphanet J Rare Dis. 2012 Aug 13;7:51
pubmed: 22889154
Biochimie. 2014 Mar;98:135-42
pubmed: 24316281